KLS-3021 An Oncolytic Viral Therapy For Prostate Cancer Could Soon Reach Clinical Trial Stage

KLS-3021 represents a promising advancement in oncolytic virus therapy, particularly for prostate cancer, where it has shown potential to address unmet needs in early and locally advanced disease. This recombinant vaccinia virus is engineered to selectively infect and lyse tumor cells while delivering a triple payload of therapeutic genes: PH-20 hyaluronidase to degrade the tumor’s […]

Dual-Action Nanomaterial Eradicates Cancer Cells And Spares Healthy Tissue

Scientists at Oregon State University have pioneered a groundbreaking nanomaterial that selectively annihilates cancer cells by harnessing the tumors’ own hostile chemical environment, while leaving healthy tissues completely unscathed. This innovative approach, detailed in a recent study published in Advanced Functional Materials, represents a major leap in chemodynamic therapy (CDT), an emerging treatment strategy that […]

Nanotech Advancement: Relief from Prostate Cancer Bone Pain on the Horizon

A promising study published this month in Science Advances introduces a promising “neuroimmunotherapy” nanocarrier called LipoNCs@pGSDMB, designed precisely for bone metastases like those in prostate cancer. This tiny, smart drug delivery system activates only in the high-oxidative-stress environment of bone tumors, fusing directly with cancer cell membranes to release its payload straight into the cell’s […]

SHR-A1921: A Next-Generation TROP2-Targeted Antibody-Drug Conjugate Shows Promise in Prostate Cancer

SHR-A1921, also known as tizetatug rezetecan, represents a significant advancement in targeted cancer therapeutics, specifically designed to exploit TROP2 overexpression in aggressive malignancies including prostate cancer. This novel antibody-drug conjugate (ADC) has demonstrated compelling preclinical activity in prostate cancer models and encouraging early clinical results across multiple solid tumors, positioning it as a potential therapeutic […]

Recent Discovery on tRNA Halves in Prostate Cancer

Tiny pieces of genetic material called tRNA halves play a surprising role in fueling prostate cancer growth, according to new research published in PLOS Biology. These molecules form when normal tRNA, short strands of RNA that help build proteins, get split in half inside cells, especially those driven by male hormones like in prostate cancer. […]

Smart Antibody Medicines: How the ALCO5 Platform Could Upgrade Targeted Cancer Therapy

ALCO5 is a new way of building “smart” cancer drugs that combine an antibody with a powerful medicine in a single, targeted package. The aim is to hit cancer cells much harder while sparing as much healthy tissue as possible, and to do this with drug types that previously could not be used in these […]

Stem Cell Breakthrough Enables Scalable Helper T Cell Therapies

Researchers at the University of British Columbia have achieved a major advance in stem cell engineering by developing a reliable method to produce helper T cells from stem cells in a controlled lab environment. This breakthrough, detailed in the journal Cell Stem Cell, tackles a persistent obstacle in cell therapy production, making treatments more affordable […]

Deciparticle Everolimus: Reviving mTOR Inhibition for Neuroendocrine Prostate Cancer?

Sapu-003, a nanoparticle-formulated version of everolimus delivered via a new platform (Deciparticle) has received approval for first-in-human Phase 1 testing in breast cancer patients, representing a major advance in intravenous oncology drug delivery. Unlike the standard oral everolimus tablet, which achieves only 10-20% bioavailability due to extensive first-pass metabolism and gastrointestinal degradation, the Deciparticle platform […]

ADI-212: Immune Cells Engineered to Beat Advanced Prostate Cancer

ADI-212 is a new type of immune cell therapy made from gamma delta T cells, the kind of immune cells that naturally go after tumors. These cells are specially engineered to attack PSMA-positive metastatic castration-resistant prostate cancer. The therapy has two smart upgrades. First, it carries a special version of IL-12, a powerful immune signal, […]

PSMA-1-DOTA: A New Ligand to Make Prostate Cancer Radioligand Therapy More Targeted

PSMA-targeted radioligand therapy (RLT) has transformed treatment for end-stage prostate cancer, offering strong tumor control in patients who have exhausted other options. However, these therapies frequently cause severe salivary gland damage, leading to debilitating dry mouth that often forces patients to stop treatment early. To overcome this, researchers at Case Western Reserve University developed PSMA-1-DOTA, […]